Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company based in Los Angeles, announced that its CEO and Chairman, John Yu, MD, will deliver a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The event is scheduled to take place from September 14-16, 2026, at the Lotte New York Palace Hotel. This presentation comes at a pivotal time for the company as it advances its lead drug candidate, ENV-105, through clinical development.
Kairos Pharma is dedicated to overcoming cancer drug resistance, a major challenge in oncology that often leads to treatment failure and disease relapse. The company leverages structural biology to identify and target mechanisms that enable cancer cells to evade therapies. ENV-105, a monoclonal antibody, targets CD105, a protein that has been implicated as a key driver of resistance and relapse in response to standard treatments. By inhibiting CD105, ENV-105 aims to reverse drug resistance and restore the efficacy of existing therapies across multiple cancer types.
The presentation at the H.C. Wainwright conference is significant for several reasons. It provides Kairos Pharma with a platform to communicate its scientific approach and clinical progress to a broad audience of institutional investors, analysts, and industry stakeholders. For the investment community, this is an opportunity to assess the company's potential to address an unmet medical need. For patients and healthcare providers, the development of ENV-105 could mean improved outcomes for those who have limited options after standard therapies fail.
The importance of tackling drug resistance cannot be overstated. According to the National Cancer Institute, drug resistance is a leading cause of cancer treatment failure, and it contributes to the majority of cancer-related deaths. Kairos Pharma's focus on this area aligns with a growing recognition in the oncology field that combination strategies and novel targets are essential to improve long-term survival rates.
Investors and industry observers will be keen to hear updates on ENV-105's clinical trials, including data on safety and efficacy. The company's presence at the conference also signals its commitment to engaging with the financial community as it seeks to advance its pipeline.
For more information about Kairos Pharma and its news, interested parties can visit the company's newsroom at https://ibn.fm/KAPA. The full press release regarding the conference presentation is available at https://ibn.fm/NrBQD.
Kairos Pharma's participation in the H.C. Wainwright conference underscores its dedication to advancing innovative cancer therapies. As the company continues to develop ENV-105, its efforts could pave the way for new treatment paradigms that overcome resistance and offer hope to patients battling cancer.
